UK markets open in 1 hour 55 minutes

Soligenix, Inc. (SNGX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.4353-0.0747 (-14.65%)
At close: 04:00PM EDT
0.4100 -0.03 (-5.81%)
After hours: 07:53PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.5100
Open0.4600
Bid0.4120 x 100
Ask0.5100 x 7100
Day's range0.4110 - 0.4680
52-week range0.3700 - 4.2000
Volume6,296,230
Avg. volume2,639,672
Market cap4.581M
Beta (5Y monthly)1.85
PE ratio (TTM)N/A
EPS (TTM)-0.7900
Earnings date13 May 2024 - 17 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est3.50
  • PR Newswire

    Soligenix Announces Pricing of $4.75 Million Public Offering

    Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced the pricing of its public offering of 11,875,000 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 11,875,000 shares of common stock at a combined public offering price of $0.40 per share and accompanying warrant for agg

  • Benzinga

    Why Is Penny Stock Soligenix Trading Higher On Monday?

    On Monday, Soligenix Inc (NASDAQ:SNGX) received an FDA orphan drug designation for the active ingredient in MarVax, the subunit protein vaccine of recombinantly expressed Marburg marburgvirus (MARV) glycoprotein, for the prevention and post-exposure prophylaxis against MARV infection. In addition to providing a seven-year term of market exclusivity upon final FDA approval, orphan drug designation also positions Soligenix to be able to leverage a wide range of financial and regulatory benefits, i

  • PR Newswire

    FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection

    Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Office of Orphan Products Development of the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient in MarVax™, the subunit protein vaccine of recombinantly expressed Marburg marburgvirus (MARV) glycopro